Jens Juul Holst's profil 

Jens Juul Holst

Curriculum in Brief
Jens Juul Holst is presently professor of Medical Physiology at the Department of Biomedical Sciences at the faculty of Health Sciences, University of Copenhagen, where he is also the vice-chairman. Since 2006 he has also been director of the Research Cluster for Diabetes and Obesity at the Faculty.
Dr Holst has pioneered the isolation and characterization of GLP-1 and discovery of the potential of GLP-1 for treatment of diabetes and obesity.

Awards and Honors

He is an elected member of the Royal Society of Science and Letters, and has received a number of awards including the Novo Nordisk Award, the Paul Langerhans Award of the German Diabetes Society, the Knud Lundbæk Award, the KFJ-award of Health Science Faculty of the University of Copenhagen, the Bagger-Sørensen Award and the prestigious Claude Bernard Award of the European Association of the Study of Diabetes.
His research group is partner of the DANORC Centre for obesity research and the UNIK-consortium "Food, Fitness & Pharma". Professor Holst is currently member of the editorial boards of Regulatory peptides, Endocrinology, Journal of Clinical Endocrinology and Metabolism, the American Journal of Physiology, and Diabetes.

Research Profile

Dr. Holst key discoveries includes the isolation and characterization of GLP-1, the discovery of the metabolic actions of GLP-1; the identification of the underlying endocrine disturbances of incretin function in diabetes and obesity; the discovery of the potential of GLP-1 for treatment of diabetes and obesity; the characterization of the metabolism of GLP-1 and of the particular importance of the dipeptidyl peptidase-4; the demonstration of the efficacy of DPP-4 stabilized analogues of GLP-1; and the demonstration of the potential of DPP-4 inhibitors for diabetes therapy.
Jens J. Holst has authored ~ 1000 scientific papers (currently about 800 listed in PubMed) which have received > 30.000 citations and he has an h-index of 85 (Web-of Science).

Recent Key Discoveries

Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas.
Identification of the detailed mode of action of incretin hormones through a paracrine mechanism identified through the use of the isolated perfused porcine pancreas model.
De Heer J, Rasmussen C, Coy DH, Holst JJ. Diabetologia 51: 2263-2270, 2008.

Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report.
Most compelling evidence that gut peptides play an essential role in the acute anti-diabetic effect of bariatric surgery.
Dirksen C, Hansen DL, Madsbad S, Hvolris LE, Naver L, Holst JJ, Worm D. 
Diabetes Care 33: 375-7, 2010.

The glucagonostatic and insulinotropic effects of glucagon-like peptide-1 contribute equally to its glucose-lowering action.
Example of the execution of a highly complex clinical protocol which demonstrates the great importance of the glucagonostatic effect of GLP-1.
Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FJ, Holst JJ.